Related Experiment Videos
Neoadjuvant therapy: an emerging concept in oncology
Tawee Tanvetyanon1, Joseph I Clark, Steve C Campbell
1Division of Hematology/Oncology, Department of Medicine, Loyola University Chicago Stritch School of Medicine, Maywood, IL, USA. ttanve@lumc.edu
Southern Medical Journal
|April 9, 2005
Summary
Neoadjuvant therapy, given before main cancer treatment, aids organ preservation in some cancers but doesn't consistently improve survival. Its benefits for other solid tumors are still under investigation.
Area of Science:
- Oncology
- Clinical Trials
- Cancer Treatment
Background:
- Neoadjuvant therapy is a key component of modern cancer care.
- It involves administering treatment before the primary intervention.
- This review focuses on common malignant solid tumors.
Purpose of the Study:
- To review the outcomes of neoadjuvant therapy for various solid tumors.
- To analyze data from large, randomized, controlled trials.
- To assess the impact of neoadjuvant therapy on survival and organ preservation.
Main Methods:
- Systematic review of randomized controlled trials.
- Data organized by primary organ affected by cancer.
- Focus on common malignant solid tumors.
Main Results:
- Organ preservation achieved in locally advanced rectal, laryngeal, and breast cancer without improving overall survival.
- Improved survival suggested in locally advanced bladder and cervical cancer, but superiority over adjuvant therapy is uncertain.
- Survival benefits for resectable non-small cell lung, esophageal, gastric, and prostate cancer are under investigation.
Conclusions:
- Neoadjuvant therapy offers organ preservation benefits in specific cancers but not overall survival improvement.
- Further research is needed to clarify the survival advantages of neoadjuvant therapy compared to adjuvant approaches.
- The role of neoadjuvant therapy in resectable non-small cell lung, esophageal, gastric, and prostate cancer requires ongoing investigation.